Mega Matrix Announced that Action-Packed Revenge Drama "License to Wed and Kill" Premiered on FlexTV on December 10
SINGAPORE, Dec. 11, 2024 /PRNewswire/ -- Mega Matrix Inc. ("MPU" or the "Company") (NYSE American: MPU), today announced that it has launched the English adaptation of the action-revenge short drama License to Wed and Kill on December 10. This...
Expanse of Drylands Must be a 'Wake-up Call' Warns Saudi Arabia's UNCCD COP16 Presidency
Sustainability Innovation Week launches with new water research center RIYADH, Saudi Arabia, Dec. 11, 2024 /PRNewswire/ -- Science Technology and Innovation Day saw delegates at COP16 in Riyadh seek to harness the restorative potential of innovation...
State Grid Kizilsu Kirghiz Autonomous Prefecture Electric Power Supply Company successfully completed the protection technology renovation of the main transformer of the 110 kV Munag substation
ARTUSH, China, Dec. 11, 2024 /PRNewswire/ -- Recently, Kizilsu Power Supply Company of the State Grid announced the successful completion of the technical transformation of the main transformer protection of the 110 kV Munag substation. With the...
2024 PHBS-CJBS Global Pitch Competition Grand Final Held
SHENZHEN, China, Dec. 11, 2024 /PRNewswire/ -- The 2024 PHBS-CJBS Global Pitch Competition, jointly hosted by Peking University HSBC Business School (PHBS) and Cambridge Judge Business School (CJBS), concluded with its grand final on December 5th at...
Pilatus Biosciences Inc. Secures FDA Orphan Drug Designation for PLT012: A Breakthrough in Liver and Intrahepatic Bile Duct Cancer Treatment
DOVER, Del. and EPALINGES, Switzerland, Dec. 11, 2024 /PRNewswire/ -- Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver...
J.F. Lehman & Company Raises $2.2 Billion for Oversubscribed Fund VI
NEW YORK, Dec. 11, 2024 /PRNewswire/ -- J.F. Lehman & Company ("JFLCO"), a leading middle-market private equity firm focused exclusively on the aerospace, defense, maritime, government and environmental sectors, today announced the successful...
Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
MinIO Research Reveals the Impact of AI on Storage Infrastructure
IT leaders see object storage as the foundation for AI and advanced analytic workloads REDWOOD CITY, Calif., Dec. 10, 2024 /PRNewswire/ -- MinIO, the leader in high-performance object storage, today announced the findings of its Object Storage and...
Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...